{"filing":{"accession_number":"0001171843-26-005292","cik":"0001738021","ticker":"CMPX","company_name":"Compass Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"f8k_080526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/f8k_080526.htm"},"events":[{"id":25473,"run_id":23124,"accession_number":"0001171843-26-005292","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Compass Therapeutics issued a press release on August 6, 2026, announcing financial results for the quarter and six months ended June 30, 2026, including net loss, R\u0026D and G\u0026A expenses, and cash position. The filing explicitly states \"On August 6, 2026, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter and six months ended June 30, 2026,\" with consolidated financial statements (income statement and balance sheet) attached as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02.","company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26312,"accession_number":"0001171843-26-005292","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Compass Therapeutics issued a press release on August 6, 2026, announcing financial results for the quarter and six months ended June 30, 2026, including net loss, R\u0026D and G\u0026A expenses, and cash position. The filing explicitly states \"On August 6, 2026, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter and six months ended June 30, 2026,\" with consolidated financial statements (income statement and balance sheet) attached as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:47:46.606659+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26312,"accession_number":"0001171843-26-005292","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Compass Therapeutics issued a press release on August 6, 2026, announcing financial results for the quarter and six months ended June 30, 2026, including net loss, R\u0026D and G\u0026A expenses, and cash position. The filing explicitly states \"On August 6, 2026, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter and six months ended June 30, 2026,\" with consolidated financial statements (income statement and balance sheet) attached as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:47:46.606659+00:00","company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","filing_date":"2026-08-06"}]}